Entropy Neurodynamics

Entropy Neurodynamics Debt Growth

The Year-over-Year Debt Growth of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is -100.00 %. In the previous year, Year-over-Year Debt Growth was -59.03 % — a change of 69.40% (lower).

Debt Growth

-100.00 %

YoY

69.40%

Last updated:

Year-over-Year Debt Growth of Entropy Neurodynamics is 2024 -100.00 % . Year-over-Year Debt Growth of Entropy Neurodynamics was 2023 -59.03 % . It decreases by 69.40% lower compared to the previous year.

The Entropy Neurodynamics Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2021
48.55 AUD
Jan 1, 2022
176.01 AUD
Jan 1, 2023
-59.03 AUD
Jan 1, 2024
-100.00 AUD
The Entropy Neurodynamics Debt Growth history
YEARDebt GrowthYoY
-100.00 %+69.40%
-59.03 %-133.54%
176.01 %+262.54%
48.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Year-over-Year Debt Growth of Entropy Neurodynamics is -100.00 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Entropy Neurodynamics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics